(NASDAQ: XFOR) X4 Pharmaceuticals's forecast annual revenue growth rate of -11.04% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 103.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.64%.
X4 Pharmaceuticals's revenue in 2025 is $33,979,000.On average, 6 Wall Street analysts forecast XFOR's revenue for 2025 to be $3,077,858,854, with the lowest XFOR revenue forecast at $2,921,959,240, and the highest XFOR revenue forecast at $3,219,331,415. On average, 6 Wall Street analysts forecast XFOR's revenue for 2026 to be $1,205,052,434, with the lowest XFOR revenue forecast at $539,834,112, and the highest XFOR revenue forecast at $2,084,840,389.
In 2027, XFOR is forecast to generate $2,753,818,489 in revenue, with the lowest revenue forecast at $1,827,951,399 and the highest revenue forecast at $3,711,075,349.